Drug intelligence / Profile preview

TLC-ART

Development stage: Unknown
Lead developer: University of Washington
Modality: Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous

Overview

TLC-ART (Targeted Long-acting Combination Antiretroviral Therapy) is a program at the University of Washington developing long-acting injectable HIV drug combinations using drug-combination nanoparticle (DcNP) technology. This platform enables multiple HIV drugs with different physicochemical properties to be formulated into stable injectable suspensions that provide sustained drug release. The program has several product candidates in development, including TLC-ART 101 (lopinavir-ritonavir-tenofovir), TLC-ART 201 (lopinavir-ritonavir-tenofovir-lamivudine), and TLC-ART 301 (tenofovir-lamivudine-dolutegravir). These formulations aim to overcome adherence challenges with daily oral HIV medications by providing sustained drug levels in lymph nodes and blood cells for up to one month after a single subcutaneous injection.

Other names: Targeted Long-acting Combination Antiretroviral Therapy

Targets

Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)

Beyond the preview

Go deeper on TLC-ART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLC-ART.

Explore the full profile